Search

Search Results

• 

  Direct oral anticoagulants in patients undergoing cardioversion: insight from randomized clinical trials

  Stefania Angela Di Fusco, Furio Colivicchi, Nadia Aspromonte, Marco Tubaro, Alessandro Aiello, Massimo Santini

  2017-05-18

  Published: May 18, 2017

  2301

  PDF: 1139
• 

  Treatment of very old patients with non valvular atrial fibrillation. The valuable opportunity offered by New Oral Anticoagulants, to be cautiously used

  Francesco Orso, Riccardo Barucci, Stefania Fracchia, Giulio Mannarino, Alessandra Pratesi, Francesco Fattirolli

  2013-12-30

  Published: December 30, 2013

  1597

  PDF: 939

• Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part I: the thromboembolic risk

  Maurizio Giuseppe Abrignani, Furio Colivicchi

  2015-11-25

  Published: November 25, 2015

  1051

  PDF: 689
• 

  Efficacy and safety of oral anticoagulant therapy in frail patients with atrial fibrillation

  Giuseppe Patti, Ludmilla Mantione, Edoardo Bressi, Antonio Bisignani

  2018-06-07

  Published: June 7, 2018

  4098

  PDF: 783

• Management strategies and choice of antithrombotic treatment in patients admitted with acute coronary syndrome - Executive summary for clinical practice

  Massimo Uguccioni, Francesco Pugliese, Leonardo De Luca, Marco Tubaro, Maria Pia Ruggieri, Furio Colivicchi

  2015-11-25

  Published: November 25, 2015

  1175

  PDF: 700

• Critical issues in megatrials on new oral anticoagulants. Rocket AF: applying results to low risk patients

  Massimo Uguccioni, Cosimo Napoletano

  2015-11-25

  Published: November 25, 2015

  970

  PDF: 618
• 

  Net clinical benefit of anticoagulation therapy in the elderly patients with atrial fibrillation

  Lorenzo Palleschi, Eleonora Nunziata

  2018-06-07

  Published: June 7, 2018

  3037

  PDF: 578

• From warfarin to new oral anticoagulants in clinical practice. What is the future of anticoagulant therapy in atrial fibrillation?

  Furio Colivicchi

  2015-11-25

  Published: November 25, 2015

  734

  PDF: 645

• Rivaroxaban in non valvular atrial fibrillation: subgroups analysis

  Cesare Greco

  2015-08-19

  Published: August 19, 2015

  1227

  PDF: 888

• Thromboembolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part II: hemorrhagic risk and guidelines recommendations

  Maurizio Giuseppe Abrignani, Vincenzo Abrignani

  2015-11-25

  Published: November 25, 2015

  987

  PDF: 581
• 

  SARS-CoV-2 induced coagulopathy and potential role of anticoagulation: Scoping review of literature

  Zehra Naseem, Muhammad Mussab Khakwani, Maaha Ayub, Ahmed Ayaz, Bushra Jamil, Ainan Arshad

  2022-01-26

  Published: January 26, 2022

  1774

  PDF: 823

• Severe heart failure and intracardiac thrombosis: going beyond the appearance for diagnosis and treatments

  Andrea Segreti, Sara Mastroberardino, Lorenzo Frau, Alessandro Appetecchia, Luca D’Antonio, Danilo Ricciardi, Gian Paolo Ussia, Francesco Grigioni

  2024-05-02

  Published: May 2, 2024

  598

  PDF_EARLY VIEW: 281
• 

  COVID-19 and coagulative axis: review of emerging aspects in a novel disease

  Matilde Boccia, Luigi Aronne, Benito Celia, Grazia Mazzeo, Maria Ceparano, Vito D'Agnano, Roberto Parrella, Tullio Valente, Andrea Bianco, Fabio Perrotta

  2020-05-19

  Published: May 19, 2020

  5413

  PDF: 2797